Drug Trial Radar · NCT06823609
Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 6, 2025
Primary completion
Nov 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.
Conditions
- Advanced Malignant Tumor
Interventions
QLS1304 tabletDrug
QLS1304 monotherapy dose escalation and expansion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limited toxicity (DLT) of QLS1304Time frame: up to 35 days
- Maximum tolerated dose(MTD)of QLS1304Time frame: up to 35 days
- Recommended Phase II Dose (RP2D) of QLS1304Time frame: up to 35 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.